medigraphic.com
ISSN 1561-3054 (Electronic)

2022, Number 1

<< Back Next >>

Rev Cubana Med Trop 2022; 74 (1)

Primoinfection by Toxoplasma gondii in pregnant women in Primary Health Care in Havana

Ginorio GDE, Hernández ÁH, Núñez FFA, Casanova AP, de-la-Torre A

Language: Spanish
References: 29
Page:
PDF size: 431.87 Kb.


ABSTRACT

Introduction: Primoinfection by Toxoplasma gondii acquired during pregnancy can cause severe clinical manifestations in the newborn parameters; it is a treatable and preventable event, though.
Objective: To describe serological evidence of primoinfection by T. gondii in pregnant women in Primary Health Care (PHC) in Havana.
Methods: A retrospective descriptive study of serological results of pregnant women screened in the PHC, Havana, from 2005 to 2011 was conducted. A total of 1820 sera were processed at the National Reference Laboratory of Parasitology of Pedro Kourí Institute (LNRP-IPK) through indirect immunofluorescence assay (IFA), VIDAS TOXO IgM and Toxo IgG Avidity. Samples with antibody titers ≥ 1/128 by IFA were tested for IgM; if positive, IgG avidity was determined.
Results: 1151 sera (63.2%) yielded negative results. Most were pregnant women between 16 and 35 years of age with an average positivity of 34.1%, without significant distinction between municipalities of origin. Anti-Toxoplasma IgG titers prevailed 1/16-1/64. In pregnant women over 35 years of age, titers were 120/209 (57.4%), a significant result when compared with the group under 16 years of age (4/14; 28.5%). IgG titers ≥ 1/128 (3.1%) appeared in 5858 women, and those under 16 years of age predominated (2/14; 14.2%). IgG and IgM were positive in 17.2% of pregnant women, a relevant aspect in Old Havana (6.8%). Low levels of avidity were found in 5/10 (index < 0.200 IgG), which represented 0.2% of the total number of pregnant women studied.
Conclusion: In pregnant women in some health areas in Havana, primoinfection by T. gondii was confirmed.


REFERENCES

  1. Fanigliulo D, Marchi S, Montomoli E, Trombetta CM. Toxoplasma gondii in women of childbearing age and during pregnancy: seroprevalence study in Central and Southern Italy from 2013 to 2017. Parasite. 2020;27(2):1-4. DOI: https://doi.org/10.1051/parasite/2019080

  2. Peyron F, L’Ollivier C, Mandelbrot L, Wallon M, Piarroux R, Kieffer F, et al. Maternal and congenital Toxoplasmosis: Diagnosis and treatment recommendations of a french multidisciplinary working group. Pathogens. 2019;8(1):24-9.

  3. Teimouri A, Mohtasebi S, Kazemirad E, Keshavarz H. Role of Toxoplasma gondii IgG avidity testing in discriminating between acute and chronic toxoplasmosis in pregnancy. J Clin Microbiol. 2020;58(9):1-13.

  4. Avelino MM, Amaral WN, Rodrigues IM, Rassi AR, Gomes MB, Costa TL, et al. Congenital toxoplasmosis and prenatal care state programs. BMC Infect Dis. 2014;14(33):1-13.

  5. Wallon M, Peyron F. Congenital Toxoplasmosis: A Plea for a Neglected. Pathogens. 2018;7(25):1-9.

  6. Prusa AR, Kasper DC, Sawers L, Walter E, Hayde M, Stillwaggon E. Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-saving. PLoS Negl Trop Dis. 2017;11(7):e0005648.

  7. Olariu TR, Remington JS, McLeod R, Alam A, Montoya JG. Severe congenital toxoplasmosis in the United States: clinical and serologic findings in untreated infants. J Ped Infect Dis. 2011;30(12):1056-61.

  8. Cortes JA, Gómez JE, Silva PI, Arévalo L, Rodriguez IA, Álvarez MI, et al. Clinical practice guideline. Integral Care Guidelines for the prevention, early detection and treatment of pregnancy, childbirth and puerperium complications: Section on toxoplasmosis in pregnancy. Infectio. 2017;21(2).

  9. Machín R, Martínez R, Fachado A, Pividal J, Bravo J. Encuesta Nacional de Toxoplasma I. Prevalencia por sexo y edades. Cuba. Rev Cubana Med Trop. 1993;45(2):146-51.

  10. García Y, Fraga J, Ginorio DE, Rodríguez MS, Cox R, Sarracent J. Toxoplasmosis y Embarazo. Reporte de un caso. Rev Mex Patol Clin. 2003;50(3):157-9.

  11. Rodríguez MS, Rodríguez D, Ginorio DE, Martínez R, Casanovas P, Fraga J, et al. Primoinfección por Toxoplasma gondii durante el embarazo. Rev Panam Infectol. 2006;8(3):43-46.

  12. Sánchez L, Couret MP, Ginorio DE, Nodarse A, Sánchez N, Soler I, et al. Toxoplasmosis y embarazo. Rev Cub Obstet Ginecol. 2012;38(1):99-106.

  13. Morán RA, Couto MJ, Peña A, Alonso RM, Pupo L, Gómez HJ. Presentación de un caso con toxoplasmosis congénita. Rev Cub Obstet Ginecol. 2016;42(1):1-4.

  14. Hernández NR, Ginorio DE, Álvarez D, Matamoro D, Castellanos I. Conocimientos sobre toxoplasmosis de las mujeres en edad fértil de un consultorio médico en Trinidad. Rev Cub de Med Gen Int. 2014;30(2):217-24.

  15. Ambroise-Thomas P, Garin JP, Rigaud A. Improvement of the immunofluorescence technic by the use of counter-dyes. Application to Toxoplasma. Presse Med. 1966;74:2215-6.

  16. Murata J-B, Darda C, Hidalgo HF, Dardéc ML, Brenier-Pincharta MP, Pellouxa H. Comparison of the Vidas System and Two Recent Fully Automated Assays for Diagnosis and Follow-Up of Toxoplasmosis in Pregnant Women and Newborns. Clin Vaccine Immunol. 2013;20(8):1203-12.

  17. Perez MI, Hervada V, Naveira G, Silva LC, Fariñas H, Vázquez E, et al. El programa Epidat: usos y perspectivas. Rev Panam Salud Publica. 2010;27(1):79-82.

  18. Machín R, Fachado A, Suárez M, Bravo R, Pividal J. Evaluación e introducción de la prueba de inmunofluorescencia indirecta (toxoplasmosis) en los servicios de diagnóstico del Instituto de Medicina Tropical “Pedro Kourí” (IPK) y su relación con la prueba de fijación del complemento. Rev Cubana Med Trop. 1988;40(1):46-53.

  19. González-Morales T, Bacallo-Galleste J, Garcia-Santana CA, Molina-Garcia JR. Prevalencia de anticuerpos anti-Toxoplasma gondii en una población de mujeres embarazadas en Cuba. Gac Méd Mex. 1995;131(5-6):499-503.

  20. Sánchez A, Martín I, García SM. Estudio de reactividad a Toxoplasma gondii en embarazadas de las provincias Ciudad de La Habana y Pinar del Río, Cuba. Bioquimia. 2003;28(2):3-8.

  21. Cruz M, Hernández A, Dorta AJ. El nexo entre biología, respuesta inmune y clínica en la infección por Toxoplasma gondii. Rev Cub Inv Biom. 2019;38(4):e256.

  22. Smith NC, Goulart C, Hayward JA, Kupz A, Miller CM, Dooren GG. Control of human toxoplasmosis. International J Parasitol. 2021;51:95-102.

  23. Maldonado YA, Read JS. AAP Committee on Infectious Diseases. Diagnosis, Treatment and Prevention of Congenital Toxoplasmosis in the United States. Pediatrics. 2017;139(2):e20163860.

  24. Flores C, Villalobos-Cerrud D, Borace J, Fábrega L, Norero X, Sáez-Llorens X, et al. Epidemiological aspects of maternal and congenital toxoplasmosis in Panama. Pathogens. 2021;10(764):1-14.

  25. Mauriello L, Diaz-Bello Z, Aponte M, Muñoz CA, Alarcón de Noya B. Fifteen years of toxoplasmosis screening at the Institute of Tropical Medicine, a Diagnostic Reference Center in Venezuela. Human Parasitic Dis. 2016;8:1-9.

  26. Soltani S, Ghaffari AD, Kahvaz MS, Sabaghan M, Pashmforosh M, Foroutan M. Detection of Anti-Toxoplasma gondii IgG and IgM Antibodies and Associated Risk Factors during Pregnancy in Southwest Iran. Infect Dis Obstet Gynecol. 2021:5547667. DOI: https://doi.org/10.1155/2021/5547667

  27. Rostami A, Riahi SM, Gamble HR, Fakhri Y, Nourollahpour Shiadeh M, Danesh M, et al. Global prevalence of latent toxoplasmosis in pregnant women: a systematic review and meta-analysis. Clin Microbiol Infect. 2020;26(6):673-83.

  28. Jankowiak Ł, Rozsa L, Tryjanowski P, Møller AP. A negative covariation between toxoplasmosis and CoVID-19 with alternative interpretations. Scientific Reports. 2020;10:12512.

  29. Fakhry E, Ibrahim MN, Mostafa NE, Moawad HS, Elgammal NE, Darwiesh EM, et al. Role of interferon gamma in SARS‑CoV‑2‑positive patients with parasitic infection. Gut Pathog. 2021;13(29):1-7.




2020     |     www.medigraphic.com